TMCnet News
InspireMD Announces Results from Initial Clinical Study of The CGuard™ Embolic Prevention System (EPS) with SmartFit™ TechnologyTEL AVIV, Israel, Jan. 22, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details of a new investigator-initiated trial entitled, “Initial Clinical Study of the New CGuard™ EPS MicroNet® Covered Carotid Stent: ‘One Size Fits All,’” at the Leipzig Interventional Course (LINC), which is being held January 22-25, 2019 in Leipzig, Germany. Prof. Christian Wissgott, from the Institute for Diagnostic and Interventional Radiology/Neuroradiology, Westkuestenklinikum Heide – Academic Teaching Hospital of the Universities of Kiel, Luebeck and Hamburg, presented his findings using a 10mm diameter CGuard™ EPS with SmartFit™ technology across a broad range of carotid artery diameters, under a differentiated concept of “One Size Fits All.” “One of the keys to successfully treating patients with carotid artery disease is to employ a device that is optimally sized,” commented Prof. Wissgott. “With variations of diameters between the common carotid artery (CCA) and the internal carotid artery (ICA), as well as x-ray images giving significant diameter errors due to projection angles, the correct size choice of a carotid stent is frequently challenging. I believe CGuard™ EPS with SmartFit™ technology overcomes this significant challenge.” Prof. Wissgott concluded through in-vitro bench testing that the “One Size Fits All” CGuard™ EPS with SmartFit™ technology demonstrated a near flat chronic outward radial force in the range of 5.5 to 9.0mm diameters, meaning the force against a vessel wall in a 5.5mm vessel and that in a 9.0mm vessel are similar. In the subsequent initial clinical study of 30 consecutive routine patients with a range of carotid artery diameters from 9.0 mm in the CCA to 5.2mm in the ICA and diameter changes between the CCA and ICA of 2.6mm, Prof. Wissgott demonstrated that, by using a 10mm diameter CGuard™ EPS in all cases, the “One Size Fits All” SmartFit™ technology readily adapts to a range of carotid artery diameter changes and offers additional protection against embolic events that can lead to stroke. The CGuard™ EPS with SmartFit™ was implanted with 100% technical success with no peri-procedural complications and no major or minor strokes at the six-month follow up. Duplex ultrasound, which measures flow thrugh the carotid artery, confirmed that all ECA (external carotid arteries) were fully patent in all cases. In addition, a subgroup of 10 patients underwent DW-MRI follow-up at 30 days and at six months with no new ipsilateral lesions observed. Dr. James Barry, President and CEO of InspireMD, Inc., commented, “Prof. Wissgott’s in vitro and initial clinical evaluations show the potential of the CGuard™ EPS with SmartFit™ technology to simplify treating patients with carotid artery disease by using a “One Size Fits All” concept for a majority of carotid artery diameters within patients, and between patients, with excellent clinical results. Additionally, the CGuard™ EPS with SmartFit™ does not forshorten when implanted as do many conventional closed-cell stents and next generation double-layer stents. This allows us to offer what we believe is the easiest-to-use carotid device and procedure available on the market today, while most importantly continuing to provide maximum protection against stroke.” About LINC About InspireMD, Inc. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS. Forward-looking Statements Investor Contacts: Jeremy Feffer |